Last checked at 
LONDON (Alliance News) - Biotechnology firm Oxford BioDynamics PLC said Tuesday it has established a US subsidiary and appointed a commercial head for the country.
In line with its strategy to expand in the US, Oxford BioDynamics has formed Oxford BioDynamics Inc. It has hired Glen Ferguson as senior vice president for the US in order to lead business activities in the country.
Ferguson joins Oxford BioDynamics from HealthTell Inc where he had been vice president for corporate development since 2014. Previously, he had held senior positions at a number of firms including Bristol-Myers Squibb Co.
He brings "significant" experienced in licensing and contract negotiation, developing strategic alliances, and expertise in the field of companion diagnostics.
"Glen is a strong addition to the OBD leadership team, bringing a wealth of experience in global corporate development and strategic partnerships," Oxford BioDynamics Chief Executive Christian Hoyar Millar said. "Glen's appointment, and the formation of our new US subsidiary, reinforce our commitment to our business development, particularly in the US, the world's largest healthcare market."
Shares in Oxford BioDynamics were 2.9% lower at 126.20 pence on Tuesday.